Author: BioactiveCompoundLibrary

In white adipocytes, the lipid ester core consists almost exclusively of triglycerides, whereas in many non-adipocytes LDs contain both TG and cholesterol esters in various ratios. TG synthesis is facilitated in the presence of excess fatty acids. In many non-adipocytes in culture, only a small number of LDs exist under normal conditions, but the addition of unsaturated fatty acids such as oleic acid to the medium induces abundant TG-rich LDs. CE metabolism has been studied most actively using macrophage foam cells, which take up significant quantities of plasma lipoproteins; in contrast, the general conditions that induce CE accumulation in other cell types are not well known. Degradation mechanisms have also been more thoroughly analyzed for TG than for CE. The regulatory mechanism of cytosolic lipases, including adipocyte triglyceride lipase and hormone-sensitive lipase, has been rapidly unveiled. In contrast, the enzymes engaged in CE hydrolysis have not been firmly established, even in macrophage foam cells. A recent study revealed that autophagy is involved in the degradation of LDs in hepatocytes, but it is not yet known in detail whether and to what extent this process is active in other cell types. In the present study, we found that treatment with protein translation inhibitors causes a significant increase in BMS-354825 CE-rich LDs. Translation inhibitors are frequently used in cell biological experiments, but the effect observed in the present study has not been given attention in the past. Earlier studies showed that treatment with cycloheximide suppresses autophagy. More recently, inhibition of protein synthesis was shown to activate mTORC1. We aimed to investigate whether the increase in CE-rich LDs that results from treatment with translation inhibitors was caused by mTORC1 activation and/ or suppression of autophagy. In the present study, we found that protein translation inhibitors cause a significant increase in CE-rich LDs. Because translation inhibitors are known to cause mTORC1 activation and autophagy suppression, we initially supposed that those processes were responsible for the increase in CE-rich LDs. Yet this increase in CE and LDs was observed even in the presence of mTORC1 inhibitors and in autophagy-deficient cells, indicating the engagement of other mechanisms. As a possible cause of the observed phenomena, we speculate that translation inhibitors may cause a down-regulation of CE hydrolysis: that is, CE hydrolytic enzymes may have a relatively short half-life and may decrease quickly when protein synthesis is suppressed. Hormone-sensitive lipase may be engaged in CE hydrolysis, but if its decrease were the main cause of the CE increase in CHX-treated cells, TG would be expected to increase simultaneously, and this was not observed in the present experiment. Other than HSL, several neutral CE hydrolases have been reported to be critical for CE digestion in macrophage foam cells, but their role in other cell types is not clear. Thus we are yet to examine the aforementioned possibility. We observed that the CHX-induced increase in CE and LDs also occurs in autophagy-deficient Atg5-null MEF, but this does not preclude the possibility that autophagy is involved in CE metabolism and LD turnover. In fact we found that significantly larger amounts of CE were observed in Atg5-deficient MEF than in wild-type MEF both before and after CHX treatment. Moreover, the PR-171 seemingly complete suppression of the autophagic flow in cells treated with CHX and Torin1 caused a significantly higher increase of CE than in cells treated with CHX alone, in which a low level of autophagy was occurring.

RAMs might determine a phenotypic drug-resistance without altering the secondary RNA-structure stability. Chronic myeloid leukemia is characterized by the constitutively activated tyrosine kinase BCR-ABL. Treatment of CML with the small molecule tyrosine kinase inhibitor imatinib stands as a paradigm for clinical efficacy of targeted small molecule therapy in malignant disease. Imatinib inhibits BCRABL tyrosine kinase activity and has been shown to effectively target the malignant clone in vitro and in vivo, resulting in a high percentage of long-term remissions in CML patients. Beyond CML, TKIs are currently either approved or evaluated in numerous other hematologic and solid neoplasms and may become cornerstones of novel treatment strategies in the near future.. Preclinical and clinical data derived from studies using imatinib and other compounds suggested that candidates for clinical development should exhibit a sufficiently long plasma half-life to facilitate persistent target inhibition: continuous exposure to imatinib concentrations $1 mM for at least 20 h is necessary to induce apoptosis in BCR-ABL transformed cells in vitro, and clinical trials demonstrated a close relationship between imatinib serum trough-levels and clinical response. Finally, the extent of BCR-ABL inhibition, as determined by the level of CRKL dephosphorylation, correlated with clinical activity. Therefore, it has been widely accepted that continuous and complete target inhibition is a prerequisite for clinical efficacy of TKI treatment. Recently, this paradigm has been challenged by data obtained in a clinical trial using the second generation BCR-ABL inhibitor dasatinib. Dasatinib demonstrated similar clinical activity but less side effects for once daily dosing with 100 mg as compared to twice daily dosing with 70 mg. Interestingly, the once daily dosing schedule apparently resulted in transient inhibition of BCR-ABL kinase activity only, as rephosphorylation of the BCR-ABL downstream adaptor protein CRKL was observed 8 h post dasatinib-dosing. In addition, in vitro and ex vivo studies suggested that high-dose pulse-exposure to TKI irreversibly commits BCR-ABL positive cells to apoptosis. This R428 effect was evident upon pulse treatment for only 20 min -4 h. It was proposed that depth, rather than duration of kinase inhibition, is the critical determinant for TKI efficacy. However, the molecular mechanism for apoptosis induction after HD-TKI pulse-exposure has remained elusive. In our present work, we demonstrate that KRX-0401 157716-52-4 dramatic intracellular drug retention mediates apoptotic cell death upon HD-TKI pulseexposure. In line with this, over-expression of ABC transporters prevented cell death upon HD-TKI pulse-exposure. These findings will be useful to rethink our current framework of pharmacokinetic requirements of TKIs for CML and other diseases. In addition, these studies refine the molecular concept of TKI-induced apoptosis. Induction of apoptosis upon HD-TKI pulse-exposure has been demonstrated by several groups. Based upon these findings, a concept of irreversible commitment to apoptosis upon HD-TKI pulse-exposure was proposed. However, the mechanism of induction of apoptosis upon HD-TKI pulse-exposure remained elusive at the molecular level. This prompted us to investigate the molecular mechanisms of cell death induced by HD-TKI pulse-exposure in more detail. It appeared unlikely that short-term potent kinase inhibition could initiate an irreversible cell death program without altering onset and kinetics of apoptosis. Indeed, the data presented here provide evidence that HD-TKI pulseexposure does not irreversibly initiate apoptosis, since cells can be completely rescued by drug wash-out.

However, MMP-mediated controlled proteolysis of the ECM, also releases protein fragments such as endostatin, canstatin, tumstatin, and endorepellin that are biologically active and PF-04217903 potent angiogenesis inhibitors. For a number of years, the tumor-inhibitory and anti-angiogenic properties of TIMPs were believed to be entirely due to their MMP inhibitory properties. As a consequence, there has been a considerable investment of resources to develop safe and effective therapeutic modalities that target MMPs. Several generations of synthetic MMP inhibitors were tested in phase III clinical trials in humans but were found to be surprisingly ineffective relative to the results obtained in preclinical trials. More recently, TIMPs have been shown to be multifunctional proteins with a number of biological activities that were independent of their MMP inhibitory properties. Inhibition of angiogenesis by TIMP-2 and TIMP-3 has been demonstrated to be independent of their ability to inhibit MMPs. Previously described studies of the structure-functional analyses of TIMP-2 revealed that the anti-angiogenic activity of TIMP-2 was present in the C-terminal end specifically in a smaller, 2.9 kDa domain in this region. Based on these studies we designed experiments to determine the region of TIMP-3 that was responsible for angiogenesis inhibition. In the present study we identified the C-terminal region of the protein to be responsible for this effect, using the property of TIMP-3 to block binding of VEGF to VEGFR-2 that we had previously reported. Short peptides were designed based on the functional domains of TIMP1. We mapped the anti-angiogenic activity of TIMP-3 to peptides in the putative Loop 6 and Tail regions of the protein. Peptides based on the Loop 5 and N-terminal domains had no angio-inhibitory activity in vitro or in vivo. Concomitantly, Loop6 and Tail peptides were effective in inhibiting laserinduced CNV in vivo. Sorsby fundus dystrophy, an autosomal dominant, fully penetrant, degenerative disease of the macula is manifested by symptoms of night blindness or sudden loss of acuity, usually in the third to fourth decades of life due to submacular neovascularization. SFD is caused by specific mutations in the tissue inhibitor of metalloproteinases-3 gene, most of which introduce an unpaired cysteine at the C-terminus of the protein. We have recently reported that S156C mutation in TIMP-3 induces increased angiogenesis and that mice lacking TIMP-3 show increased laser-induced CNV. Since the anti-angiogenic activity of TIMP-3 lies in the C-terminus region of the protein and most of the new cysteines in SFD mutations lie in the same region we hypothesized that Loop 6 and Tail peptides of TIMP-3 might be critical determinants of this inhibitory activity. Whether the free cysteine in the tail peptide sequence is critical for the angiogenesis inhibition will be an interesting question to address in Tubacin future studies. Sequence comparison and alignment between a short peptide sequence of pigment epithelial growth factor that shows anti-angiogenic activity and TIMP-3 shows a short consensus sequence of SNFGYXXY between the two proteins. Both PEDF and TIMP-3 are anti-angiogenic proteins whose peptides have been shown to play a critical role in inhibiting ocular angiogenesis especially choroidal neovascularization. Finding consensus sequences in these peptides might provide clues regarding the mechanisms of inhibition of neovascularization.

It is the causative agent of anthrax, a typically fatal disease affecting both humans and animals with an estimated human LD50 of 2,500�C25,000 spores via the inhalation route. There are three clinical types of anthrax that are delimited by the route of transmission: inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax. When spores, which are highly resistant to disinfection, are inhaled, ingested, or come into contact with a skin lesion on a host, they reactivate and multiply rapidly. Currently FDA-approved therapies include ciprofloxacin, doxycycline and penicillin in adults and children. A facultative intracellular gram-negative bacterium, FT is the causative agent of tularemia, a highly Kinase Inhibitor Library distributor infectious disease of humans and rabbits with an estimated human LD50 of less than 10 bacteria. The infection is spread by inhalation or skin lesions or through ingestion of contaminated soil, food or water. The FDA-approved therapy includes ciprofloxacin and doxycycline. Resistance to these drugs can be introduced very rapidly and both BA and FT have the potential for weaponization using airborne exposure making them dangerous biological threat agents. Coxiella burnetii, an obligate intracellular gram-negative pathogen, is the causative agent of Q fever. This organism is classified by the Centers for Disease Control as a Category B threat agent and is spread via inhalation. As the infectious dose is as low as a few organisms, CB one of the most infectious pathogens known. Additionally, because CB is extremely resistant to desiccation and regular disinfectants, it has the potential to be aerosolized and disseminated as a biological weapon. While not as lethal as BA or FT, Q fever is a severely debilitating disease that can be difficult to diagnose. The only FDA-approved therapy is doxycycline, but co-trimoxazole is utilized as well. Both EBOV and MARV belong to the filoviridae family and exhibit high fatality rates. Ebola virus, the causative agent for Ebola hemorrhagic fever, exhibits person-toperson transmission through body fluids and oral exposure. Under laboratory conditions, EBOV is highly infectious by aerosols. Marburg virus is the causative agent of Marburg hemorrhagic fever and exhibits very similar disease symptoms with EBOV infection. Infection by MARV is also thought to be spread by aerosols. An arenavirus, LASV is the causative agent of Lassa hemorrhagic fever and has an associated mortality of,30%. This disease is directly transmitted from human to human by contact with blood, urine, semen or breast milk. Questionable efficacy is provided by intravenous use of ribavirin and interferon gamma for LASV. There is no FDA-approved therapy for these three viruses. These agents are also emerging pathogens and if released, they are likely to overwhelm medical and public health systems and cause civil disruption. Due to the demanding complexity of working with these agents under laboratory conditions as well as the fact that drug clinical trials are not possible, conventional drug discovery and development approaches are particularly challenging. For these agents, the FDA must evaluate the efficacy of drugs on the basis of their activities in appropriate animal models, under an FDA guidance referred to as animal rule approval. Given the fact that human Tasocitinib safety studies have already been conducted, drug repurposing offers many advantages in this scenario.

There are several examples of successful drug repurposing in clinical medicine: buproprion was originally developed to treat GSK212 871700-17-3 depression but was repurposed for smoking cessation, and duloxentine was developed for treating depression but is currently marketed for treating stress urinary incontinence. This precedent for successful repurposing motivated us to screen FDA-approved drugs against a panel of biological threat agents. The most promising confirmed in vitro hits were then tested in animal models to evaluate efficacy and the potential for drug repurposing. Our screening data and many in vitro studies have suggested that CQ inhibits a number of viral pathogens through nonspecific effects on cell entry events. The generally accepted mechanism is that CQ is a lysosomatropic agent that accumulates in endosomal compartments, where it interferes with acidification, alters vesicle sorting, and inhibits the events that trigger fusion and release of viral components into the cytosol. In the case of EBOV, the mechanism of CQ appears in part to be due to its wellcharacterized inhibitory effects on the pH-dependent cathepsins B and L, which have been shown to play essential and accessory roles, respectively, in EBOV GP processing events prior to fusion. Our data further show that at the concentration tested, CQ directly perturbs virus trafficking, leading to the formation of what appear to be aggregates of accumulated virus particles. In this case, CQ appears to inhibit progression of EBOV through the cell, in addition to potential effects on proteolytic processing. It is currently unclear which mechanism is most important for the observed effects of CQ in vitro and in vivo. In addition to its R428 impact on viral trafficking, CQ has been shown to interfere with viral replication by impairing the glycosylation machinery in the Golgi that would direct trafficking and maturation of nascent viral proteins. This is thought to be the major mechanism by which CQ inhibits HIV and may also affect filoviruses and influenza, which are dependent on glycosylation for both cell attachment and uptake. CQ has also been demonstrated to inhibit endocytic toll-like receptor signaling, which may have in vivo effects on key innate responses that depend on endosomal recognition of pathogen nucleic acids or other components. A large body of evidence implicates CQ in the inhibition of the entry processes of diverse viral families and suggests that this may be a valid approach to repurpose an inexpensive, widely available drug as a much-needed countermeasure in either a mono- or combination therapy. Our results provide further evidence that nonspecific inhibitors of viral entry would be a valuable complement to the antiviral arsenal and might also be considered as elements of combination therapy with more specific inhibitors. Despite the encouraging in vitro data on the efficacy of CQ as an antiviral, previous studies that have sought to demonstrate its in vivo efficacy have been less successful. Studies in mouse models of influenza and in hamster and ferret models of Nipah virus have failed to demonstrate that CQ affects the duration or severity of disease. Clinical studies of CQ monotherapy against Chikungunya and Dengue virus show that when CQ is dosed as for antimalarial use against an established human viral infection, it does not appear to impact disease severity or time to resolution.